Lakefront Biotherapeutics NV (LKFT) - Total Liabilities
Based on the latest financial reports, Lakefront Biotherapeutics NV (LKFT) has total liabilities worth $87.52 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See LKFT defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Lakefront Biotherapeutics NV - Total Liabilities Trend (2022–2025)
This chart illustrates how Lakefront Biotherapeutics NV's total liabilities have evolved over time, based on quarterly financial data. Check Lakefront Biotherapeutics NV (LKFT) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Lakefront Biotherapeutics NV Competitors by Total Liabilities
The table below lists competitors of Lakefront Biotherapeutics NV ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
China National Gold Group Gold Jewellery Co Ltd
SHG:600916
|
China | CN¥6.12 Billion |
|
Shandong Pharmaceutical Glass Co Ltd
SHG:600529
|
China | CN¥1.76 Billion |
|
Engineers India Limited
NSE:ENGINERSIN
|
India | Rs27.24 Billion |
|
Beijing Cisri Gaona Materials Tech
SHE:300034
|
China | CN¥3.46 Billion |
|
Genesis Energy LP
NYSE:GEL
|
USA | $4.30 Billion |
|
BTG Hotels Group Co Ltd
SHG:600258
|
China | CN¥12.28 Billion |
|
Zhejiang Jinke Peroxides Co Ltd
SHE:300459
|
China | CN¥1.68 Billion |
|
Shenzhen Topband Co Ltd
SHE:002139
|
China | CN¥6.61 Billion |
Liability Composition Analysis (2022–2025)
This chart breaks down Lakefront Biotherapeutics NV's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see LKFT total asset value.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 32.82 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.03 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.03 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Lakefront Biotherapeutics NV's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Lakefront Biotherapeutics NV (2022–2025)
The table below shows the annual total liabilities of Lakefront Biotherapeutics NV from 2022 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $170.65 Million | -86.22% |
| 2024-12-31 | $1.24 Billion | -20.68% |
| 2023-12-31 | $1.56 Billion | -29.28% |
| 2022-12-31 | $2.21 Billion | -- |
About Lakefront Biotherapeutics NV
Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in… Read more